Endometrial Cancer Clinical Trial
Official title:
The Role of Functional MRI and Doppler Sonography in Assessing Intratumoral Angiogenesis of Endometrial Cancer Patients
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is
the treatment of choice in patients with noninvasive or locally advanced disease. The
surgical technique consists of an exploratory laparotomy, with total hysterectomy, bilateral
oophorectomy, peritoneal washing, and, in selected high-risk patients, omental and
peritoneal biopsies and lymphadenectomy. Therefore, preoperative clinical and instrumental
staging of the local spread of disease, as well as local and distant lymph node involvement,
represent a critical step in tailoring the extent and the radicalness of surgery.
The role of angiogenesis in cancer growth and metastasis has been gaining much attention for
decades. Recent clinical evidence supports this notion. The gradual increase in angiogenesis
intensity with tumor progression in malignant melanoma has been reported. Abulafia et al.
reported that increasing angiogenicity could be noted from simple hyperplasia, complex
hyperplasia, atypical hyperplasia, and Stage IA endometrial carcinoma to invasive
endometrial carcinoma. The investigators' research team has shown that incremental
angiogenesis could be demonstrated in the tumorigenesis and the possibility of lymph node
metastasis in endometrial malignancy. Besides, other growth factors such as vascular
endothelial growth factor (VEGF), transforming growth factor- (TGF-), IL-6 and IL-8 have
also been reported to correlate with the angiogenesis and the metastasis of endometrial
cancer. It seems that tumor angiogenesis of endometrial cancer could be utilized as an
important parameter to assess the disease severity of the endometrial cancer.
So, the investigators would like to propose this proposal to focus on the tumor angiogenesis
in endometrial cancer patients. There are several purposes in this study. First, the
investigators will evaluate and compare tumor angiogenesis surveyed from functional MRI and
power Doppler sonography in endometrial cancer patients who receive surgery. Second, the
investigators will evaluate whether tumor angiogenesis could be a marker to predict the
disease severity of endometrial cancer. Third, the role of functional magnetic resonance
imaging (MRI) in endometrial cancer will be elucidated.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Endometrial cancer patients with histopathologic proof who are arranged to receive staging surgery. - All of the patients who will be enrolled into this study need to sign the consent form and the study protocol will be under the approval of the Institutional Review Board of the patient's hospital. Exclusion Criteria: - Tumors of histologic types other than adenocarcinoma and adenoacanthoma will be excluded. |
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |